However, tumor uptake of 111In-cixutumumab was significantly higher (p < 0.0001) than 111In-cixutumumab-PEG6-DM1-High, indicating a lower binding to IGF-1R of the radioimmunoconjugate in vivo. The gene discussed is IGF1R; the disease is neoplasm.